Brace yourself: Saliva could revolutionize disease detection, but the science isn’t fully polished yet.
Saliva carries a treasure trove of microbial clues about your overall health and is easier to collect than blood. Today, a few drops can help reveal viruses such as HIV and the one behind COVID-19, and they can even assess genetic risks for conditions like breast cancer. In the near future, researchers expect similar spit-based tests to aid in diagnosing other illnesses, including diabetes and prostate cancer.
“Preventive care beats reactive care,” says Wallace Bellamy, a Sacramento dentist and president of the National Dental Association, which champions health equity. If spit tests become routine in dental care, they could save lives and reduce costs by catching diseases earlier. The hitch is cost and coverage: insurance coverage remains a major obstacle. Many patients want to know whether a test is covered, and currently it often isn’t. Home or dental-office tests typically cost between $100 and $200, with samples mailed to a specialized lab for analysis. Bellamy doesn’t offer these tests in his practice, but he reviews results for patients who bring in online orders.
Current landscape and FDA status
Salivary tests can be highly accurate for certain conditions, such as detecting cavities or identifying oral cancer in some cases. However, most saliva-based tests used by consumers are developed by individual labs and aren’t FDA-approved, meaning they haven’t undergone the extensive reliability studies the FDA requires. The few FDA-approved saliva diagnostics so far target HIV and COVID-19.
One notable player in the non-FDA-approved space is OrisDX, a Chicago-based company planning to launch a saliva test for head and neck squamous cell cancers with about 93% reliability. Samples would be collected at a dentist’s office or via dental telehealth and sent to a single lab for processing. The CEO argues there’s a large unmet need for earlier cancer detection beyond traditional visual and tactile checks.
Incentives and progress
Congress recently passed a spending measure that directs Medicare to cover FDA-approved multicancer detection tests, regardless of whether they use blood, saliva, or other methods. Regulatory experts believe this creates a strong incentive for companies to pursue full FDA approval, since national reimbursement would unlock widespread private payer adoption as well.
But saliva testing faces ongoing challenges. Purnima Kumar of the University of Michigan notes that saliva is highly variable: its composition shifts after brushing, drinking, eating, or smoking, and it differs across individuals. Researchers are race-testing salivary markers to find reliable indicators that work across diverse populations. If successful, saliva tests could lower access barriers, especially for people in rural areas or those who struggle to attend frequent dental visits.
Practical outlook
Even with improvements, experts agree saliva tests should complement—not replace—in-person care. Think of them as health-alert tools: convenient, noninvasive signals that prompt further evaluation, much like cholesterol or liver tests do in standard medicine. For busy people, a quick salivary check during a dental visit could offer a heads-up that something isn’t right and point you toward appropriate follow-up care.
What this means for you
If you’re considering a saliva-based test, weigh the cost, confirm whether your insurer will cover it, and remember that regulatory approval matters for reliability. As the field evolves, these tests may become more common and affordable, offering an additional, noninvasive route to monitor health between traditional medical visits.
Discussion prompts: Do you think saliva-based screening will become a routine part of preventive care? Should insurers cover these tests even when FDA approval is still pending, given the potential public health benefits? Share your thoughts in the comments.
